Literature DB >> 18303077

High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome.

Roderick F A de Lind van Wijngaarden1, Barto J Otten, Dederieke A M Festen, Koen F M Joosten, Frank H de Jong, Fred C G J Sweep, Anita C S Hokken-Koelega.   

Abstract

CONTEXT: The annual death rate of Prader-Willi syndrome (PWS) patients is very high (3%). Many of these deaths are sudden and unexplained.
OBJECTIVE: Because most deaths occur during moderate infections and PWS patients suffer from various hypothalamic insufficiencies, we investigated whether PWS patients suffer from central adrenal insufficiency (CAI) during stressful conditions.
DESIGN: Overnight single-dose metyrapone tests were performed. Metyrapone (30 mg/kg) was administered at 2330 h. At 0400, 0600, and 0730 h, ACTH, 11-deoxycortisol, cortisol, and glucose levels were measured. Diurnal salivary cortisol profiles were assessed on a different day at wake-up, 30 min after wake-up, at 1400 h, and at 2000 h.
SETTING: The study was conducted in a pediatric intensive care unit. PATIENTS: Patients included 25 randomly selected PWS patients. MAIN OUTCOME MEASURE: Patients were considered as having CAI when ACTH levels remained below 33 pmol/liter at 0730 h.
RESULTS: Median (interquartile range) age was 9.7 (6.8-13.6) yr. Fifteen patients (60%) had an insufficient ACTH response (CAI, P < 0.001). There was no significant difference in age, gender, genotype, and body mass index SD score between patients with CAI and those without. Morning salivary cortisol levels and diurnal profiles were normal in all children, suggesting that CAI becomes apparent only during stressful conditions.
CONCLUSIONS: Strikingly, 60% of our PWS patients had CAI. The high percentage of CAI in PWS patients might explain the high rate of sudden death in these patients, particularly during infection-related stress. Based on our data, one should consider treatment with hydrocortisone during acute illness in PWS patients unless CAI has recently been ruled out with a metyrapone test.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303077     DOI: 10.1210/jc.2007-2294

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

Review 1.  Hypoglycemia in critically ill children.

Authors:  E Vincent S Faustino; Eliotte L Hirshberg; Clifford W Bogue
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

Review 2.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

Review 3.  Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update.

Authors:  Merlin G Butler; Jennifer L Miller; Janice L Forster
Journal:  Curr Pediatr Rev       Date:  2019

4.  Approach to the child with prader-willi syndrome.

Authors:  Jennifer L Miller
Journal:  J Clin Endocrinol Metab       Date:  2012-11       Impact factor: 5.958

5.  Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes.

Authors:  G Grugni; D Giardino; A Crinò; F Malvestiti; L Ballarati; G Di Giorgio; P Marzullo
Journal:  J Endocrinol Invest       Date:  2010-07-22       Impact factor: 4.256

6.  Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice.

Authors:  Alysa A Tennese; Rachel Wevrick
Journal:  Endocrinology       Date:  2011-01-19       Impact factor: 4.736

7.  The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing.

Authors:  Shivendra Kishore; Amit Khanna; Zhaiyi Zhang; Jingyi Hui; Piotr J Balwierz; Mihaela Stefan; Carol Beach; Robert D Nicholls; Mihaela Zavolan; Stefan Stamm
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

8.  Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.

Authors:  Jennifer L Miller; Jonathan Shuster; Douglas Theriaque; Daniel J Driscoll; Mary Wagner
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

9.  Prader-Willi syndrome.

Authors:  Suzanne B Cassidy; Daniel J Driscoll
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

10.  Short-term effects of growth hormone treatment on the upper airways of non severely obese children with Prader-Willi syndrome.

Authors:  A Salvatoni; E Veronelli; L Nosetti; J Berini; S de Simone; L Iughetti; L Bosio; G Chiumello; G Grugni; G Delù; P Castelnuovo; G Trifirò; L Nespoli
Journal:  J Endocrinol Invest       Date:  2009-05-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.